Investors of LifeMD Urged to Take Action Following Securities Investigation by Faruqi & Faruqi

LifeMD Investors Take Note: Class Action Alert

Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of shareholders in LifeMD, Inc. (traded on NASDAQ under the ticker LFMD). This investigation arises from allegations that LifeMD and its executives violated federal securities laws, leading to significant financial losses for its investors.

Overview of the Situation

The firm is particularly interested in the period from May 7, 2025, to August 5, 2025, during which investors may have been adversely affected. Key legal representative James (Josh) Wilson invites those who sustained losses during this timeframe to reach out to discuss their legal rights and options. This communication is crucial for investors who wish to seek recovery for their financial damages.

On August 5, 2025, LifeMD released its financial results for the second quarter of the year, announcing a sharp downward revision of its revenue guidance. Initially projecting revenues to be between $268 to $275 million, the company had to revise this estimate to a much lower range of $250 to $255 million. This discrepancy contributed to a drastic decline in the company's stock price, plunging by approximately 44.8% on August 6, 2025.

Allegations Against LifeMD

The core of the allegations centers around claims that LifeMD misrepresented its competitive position and failed to adequately consider rising customer acquisition costs for key products in its RexMD segment. The issues pertain specifically to the costs associated with acquiring customers for drug offerings including drugs designed to treat obesity. Investors assert that these failed disclosures and misleading statements materially impacted their investment decisions, particularly in light of the significant financial losses that ensued.

Faruqi & Faruqi reminds potential claimants that the deadline for seeking the role of lead plaintiff in the federal securities class action is set for October 27, 2025. This position is especially important as the lead plaintiff plays a pivotal role in directing the litigation on behalf of all affected investors.

Participation in the Class Action

Investors who wish to join the class action lawsuit can either choose to take on the role of lead plaintiff or opt to remain as absent class members. It's essential to recognize that a decision to serve as a lead plaintiff does not impact an investor's eligibility to share in any potential recovery resulting from the case.

If you have information regarding LifeMD’s conduct, Faruqi & Faruqi encourages you to come forward. The firm is interested in talking to whistleblowers, current and former employees, as well as shareholders who may have additional insights.

Contact Information

To explore further details about the LifeMD class action or to discuss your individual case, please contact Faruqi & Faruqi’s partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). More information can also be found on their official website, Faruqi & Faruqi.

This situation underscores the need for vigilance among investors. As the landscape of securities law continues to evolve, participants in the market must remain informed and proactive in protecting their investments. Legal outcomes often depend on swift and decisive action, particularly in light of the rapidly changing financial environment.